Efficacy of Yiqi Yangyin Sanjie Formula Combined with Basic Treatment on Patients with Advanced Lung Squamous Cell Carcinoma and Its Effect on Cellular Immunity
Objective To analyze the clinical efficacy of using Yiqi Yangyin Sanjie Formula combined with Paclitaxel,Carboplatin,and Tislelizumab in the treatment of patients with advanced non-small cell lung cancer(NSCLC)(squamous cell carcinoma)and its impact on patients'cellular immunity levels.Methods A total of 120 NSCLC patients admitted to the Oncology Department of Nanyang Central Hospital from October 2021 to September 2023 were selected as study subjects.According to whether patients received only the basic treatment of Paclitaxel,Carboplatin,and Tislelizumab or were additionally treated with the Yiqi Yangyin Sanjie Formula,patients were divided into the conventional group(60 cases)and the Chinese medicine combination group(60 cases).The clinical efficacy of different treatment cycles between the two groups was compared,as well as the expression levels of tumor markers and cellular immunity-related indicators before and after treatment.The differences in the incidence of toxic side effects and complications during treatment were statistically compared between the two groups.Results After four cycles of treatment,there was no statistically significant difference in the Overall Response Rate(ORR)and Disease Control Rate(DCR)between the two groups(P＞0.05).After eight cycles of treatment,the ORR and DCR in the Chinese medicine combination group were significantly higher than those in the conventional group,with statistically significant differences(P＜0.05).Before treatment,there was no statistically significant difference in the levels of tumor markers CEA,CYFRA21-1,and CA125 between the two groups(P＞0.05).After treatment,the levels of the above tumor markers in both groups were significantly lower than before treatment,with statistically significant differences(P＜0.05);the levels of CEA,CYFRA21-1,and CA125 in the Chinese medicine combination group were significantly lower than those in the conventional group,with statistically significant differences(P＜0.05).Before treatment,there was no statistically significant difference in the levels of cellular immunity-related indicators CD3+T lymphocytes,CD4+T lymphocytes,CD8+T lymphocytes,and NK cells between the two groups(P＞0.05).After treatment,the levels of CD3+T lymphocytes and CD4+T lymphocytes in both groups were significantly higher than before treatment,while CD8+T lymphocytes were significantly lower.NK cell levels in the Chinese medicine combination group were significantly higher than before treatment,with statistically significant differences(P＜0.05);the levels of CD3+T lymphocytes,CD4+T lymphocytes,and NK cells in the Chinese medicine combination group were significantly higher than those in the conventional group,while CD8+T lymphocytes were significantly lower,with statistically significant differences(P＜0.05).Except for alopecia,the incidence of bone marrow suppression,gastrointestinal reactions,liver function damage,and kidney function damage during treatment in the Chinese medicine combination group was significantly lower than that in the conventional group,with statistically significant differences(P＜0.05).Conclusion The combination of Yiqi Yangyin Sanjie Formula with Paclitaxel,Carboplatin,and Tislelizumab helps to improve the clinical treatment effect in patients with advanced NSCLC squamous cell carcinoma,enhances the patients'cellular immune condition,and reduces the incidence of toxic side effects and complications during treatment,achieving relatively ideal application results.
国家科技期刊平台
NSTL
万方数据
